ArticleNature communications2023

Candidate mechanisms of acquired resistance to first-line osimertinib in EGFR-mutated advanced non-small cell lung cancer.

Juliann Chmielecki et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.